GlassScriptPhysician profile
Joel S Erickson
NPI 1407899479
$3,128.11
in general payments reported to CMS, 2019-2025
23 companies · $65.04 in 2025
The $65.04 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $351 · 2021: $787 · 2022: $497 · 2023: $857 · 2024: $176 · 2025: $65.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,088 · Education: $10.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.61 |
| Education | $10.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $965.71 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $306.13 | 2020-2023 | Eliquis |
| Medtronic, INC. | $289.07 | 2021-2023 | Micra |
| Merz North America, INC. | $250.00 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $247.09 | 2021-2024 | Farxiga |
| Pfizer INC. | $232.26 | 2019-2024 | |
| Amgen INC. | $113.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $106.31 | 2019-2022 | |
| Galderma Laboratories, L.P. | $100.09 | 2021-2023 | Dysport |
| Boston Scientific Corporation | $71.79 | 2022-2024 | Watchman Access System, Watchman Flx |
| Revance Therapeutics, INC. | $65.04 | 2025 | Daxxify |
| Merck Sharp & Dohme LLC | $60.41 | 2023 | Verquvo |
| Edwards Lifesciences Corporation | $56.02 | 2019-2020 | |
| Amarin Pharma, INC. | $42.66 | 2021 | |
| Allergan, INC. | $39.64 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $30.53 | 2021-2022 | |
| Heartflow, INC. | $27.90 | 2019 | |
| Abbvie INC. | $23.79 | 2023 | |
| Novartis Pharmaceuticals Corporation | $22.57 | 2019 | |
| Tactile Systems Technology INC | $22.07 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.89 | 2021 | |
| Medtronic Vascular, INC. | $18.35 | 2020 | |
| Esperion Therapeutics, INC. | $17.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.